

ASX/Media Release

19 November 2018

Results of Annual General Meeting

Perth 19 November 2018: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that the Annual General Meeting of the Company was held today, 19 November 2018. All resolutions put to the meeting were passed on a show of hands. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the resolutions and the proxies received in respect of each resolution are set out below:

Resolutions		For	Against	At Proxy Holders Discretion	Abstain/ Excluded
1	Adoption of Remuneration Report (non-binding)	107,919,786	3,307,026	1,261,950	87,074,628
2	Re-election of Director –Mr William Bosch	179,968,794	2,820,811	16,737,450	36,335
3	Approval of 10% Placement Capacity	178,519,094	4,179,511	16,765,950	98,835
4	Ratification of issue of Shares to various sophisticated and professional investors under ASX Listing Rule 7.1	162,227,308	973,895	16,760,950	19,601,237
5	Approval of issue of securities under Employee Securities Incentive Plan.	107,963,462	3,364,215	1,178,920	87,056,793
6	Approval of proportional takeover provisions in Constitution	178,742,240	3,973,700	16,768,950	78,500

For more information, please contact:

General enquiries

Matt Callahan
Botanix Pharmaceuticals
Founder & Executive Director
+1 215 767 4184
mcallahan@botanixpharma.com

Investor enquiries

Joel Seah
Vesparum Capital
P: +61 3 8582 4800
botanixpharma@vesparum.com

Media enquiries

Julia Maguire
The Capital Network
P: +61 419 815 386
julia@thecapitalnetwork.com.au

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage medical dermatology company based in Perth, Australia and Philadelphia, PA. The Company's focus is the development of safe and effective topical treatments for acne, psoriasis, atopic dermatitis and other skin conditions. The active ingredient contained in Botanix products is a synthetic form of a widely studied natural compound. Treatment targets include inflammation, deterioration of the skin barrier, skin cell proliferation, pruritus (itch), excess sebum production and bacterial infection.

Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases. Botanix is working with multiple parties to test the application of Permetrex™ on both a fee-for-service and traditional license basis.

Botanix pursues a rapid clinical development strategy aimed at accelerating product commercialisation. The patient treatment duration of clinical studies is generally completed within a 4 to 12-week timeframe.

The Company completed its first acne patient studies with BTX 1503 in January 2018 and has commenced a Phase 2 clinical trial in June 2018 with completion expected in mid-2019. The Phase 1b BTX 1204 atopic dermatitis patient study concluded in June 2018 and preparation is underway for a Phase 2 clinical trial. The Phase 1b BTX 1308 psoriasis patient study has commenced in September 2018.

To learn more please visit: <https://www.botanixpharma.com/>